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all diagnoses was 146, 149, and 114 days for olanzapine,
risperidone and quetiapine respectively. Mean duration of
therapy varied widely by diagnostic conditions (190, 202
& 171 days for schizoaffective disorder, 146, 131 & 121
days for PTSD all for olanzapine, risperidone and queti-
apine respectively). Concomitant use of more than one
atypical antipsychotic medication occurred in 17–25% of
patients, and most commonly with quetiapine. Concomi-
tant use of any other psychotropic medication was similar
in subjects receiving risperidone, olanzapine, and queti-
apine (85, 86, 85% respectively). Twenty-two percent of
patients switched atypical therapy at some point during
the study period. Of patients who had received therapy
for at least 10 weeks and switched atypical, the most
common switching occurred from olanzapine to quetiap-
ine (48%). CONCLUSIONS: Dosing and duration of
therapy of atypical antipsychotics in the Cleveland VA
varies widely between diagnostic conditions.
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OBJECTIVE: Time to treatment discontinuation for any
cause was previously identiﬁed as an important outcome
parameter in the medication management of schizophre-
nia. This study compared four antipsychotics—olanzap-
ine, risperidone, quetiapine, and haloperidol—on the time
to all-cause discontinuation. METHODS: Participants (N
= 964) were new initiators of olanzapine, risperidone,
quetiapine or haloperidol in the Schizophrenia Care and
Assessment Program (SCAP), a 3-year longitudinal,
observational study of schizophrenia. Time to all-cause
discontinuation of the antipsychotic during the 1 year fol-
lowing its initiation was measured by a) the total number
of days on the antipsychotic, and b) the number of days
of continuous treatment up to the ﬁrst gap of >14 days.
Analyses employed Mantel-Haenszel and Cox propor-
tional hazard model. Results were further conﬁrmed
using a mixed model approach. RESULTS: Olanzapine-
treated patients were on their medication signiﬁcantly
longer than patients receiving risperidone, quetiapine, or
haloperidol. Compared with olanzapine, the likelihood 
of discontinuation was 26%, 54%, and 158% greater
among patients receiving risperidone, quetiapine, or
haloperidol, respectively. CONCLUSION: Antipsy-
chotics were found to signiﬁcantly differ in the time to
all-cause discontinuation, such that olanzapine-treated
patients evidenced the longest time to discontinuation,
followed by risperidone, quetiapine, and haloperidol.
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OBJECTIVES: Recent changes to the formulary status 
of selective serotonin reuptake inhibitors (SSRIs) at our
institution, notably the removal of sertraline and avail-
ability of generic ﬂuoxetine, have altered the selection of
the most cost-effective SSRI. Objective of this protocol is
to evaluate the effect of physician proﬁling and academic
detailing on the utilization and cost of SSRIs in a staff-
model managed care organization. METHODS: A retro-
spective review of 71,801 SSRI pharmacy prescription
claims was performed for CY 2002. Following removal
of sertraline from the formulary (average monthly copay-
ment increased from $20 to $43 after removal), a volun-
tary program to encourage conversion to a formulary
alternative (paroxetine, citalopram, or generic ﬂuoxetine)
was initiated. A physician prescribing report program,
supplemented with academic detailing, was implemented
highlighting SSRI utilization and formulary and pricing
concerns. Prescriptions, patients (utilizing members), and
drug costs were measured. RESULTS: In January 2002,
the number of prescriptions was 2537 (44.9% of SSRI
market share) and 1186 (21%) for sertraline and generic
ﬂuoxetine, respectively. By December 2002, the corre-
sponding prescription numbers were 1039 (16.5%) and
2601 (41.7%). For CY 2002, the number of utilizing
members for sertraline decreased from 2415 to 982 and
increased from 1116 to 2454 for generic ﬂuoxetine. 
Prescription claims for other SSRIs remained relatively
constant. Net health plan savings in CY 2002 were
$584,369, primarily as a result of the conversion from
sertraline to generic ﬂuoxetine. CONCLUSIONS: Al-
though conversion of sertraline to non-formulary status
greatly assisted in this program, a signiﬁcant industry-
based marketing effort also began to direct those patients
to either paroxetine or citalopram ($20 monthly copay-
ments for each). However, the combination of physician
proﬁling and academic detailing was associated with an
increase in utilization of less-expensive generic ﬂuoxetine
as opposed to further gains by other formulary SSRIs.
Estimated annual savings for CY 2003, based on current
SSRI utilization, are at least $975,536.
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